Natalizumab and progressive multifocal leukoencephalopathy

Reviews in Neurological Diseases

Volumn 2, Issue 3, 2005, Pages 144-149

  Tyler, Kenneth L ^a   Khalili, Kamel ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

AIDS; Cell mediated immunity; HIV associated PML; JC virus; Multiple sclerosis; Natalizumab; Papovaviruses; Progressive multifocal leukoencephalopathy

Indexed keywords

ALPHA INTERFERON; CAMPTOTHECIN; CHLORPROMAZINE; CIDOFOVIR; CYTARABINE; CYTOKINE; ENZYME INHIBITOR; INTERLEUKIN 12 ANTIBODY; MIRTAZAPINE; NATALIZUMAB; NUCLEOSIDE DERIVATIVE; SEROTONIN 2A ANTAGONIST; TOPOTECAN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BLOOD BRAIN BARRIER; BONE MARROW SUPPRESSION; CELLULAR IMMUNITY; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG MECHANISM; HUMAN; IMMUNOPATHOGENESIS; IMMUNOPATHOLOGY; IMMUNOTHERAPY; JC VIRUS; LYMPHATIC DRAINAGE; MOLECULAR BIOLOGY; MULTIPLE SCLEROSIS; NEUROIMAGING; NONHUMAN; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; VIRUS DETECTION; VIRUS INFECTION; VIRUS LATENCY; VIRUS REACTIVATION; VIRUS REPLICATION;

ANTIBODIES, MONOCLONAL; ANTIVIRAL AGENTS; GENE EXPRESSION REGULATION, VIRAL; HUMANS; JC VIRUS; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; MULTIPLE SCLEROSIS; VIRUS REPLICATION;

EID: 26044483260     PISSN: 15452913     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (23)

1. Seth P, Diaz F, Major EO. Advances in the biology of JC virus and induction of progressive multifocal leukoencephalopathy. J Neurovirol 2003;9:236-246.
2. Sabath BF, Major EO. Traffic of JC virus from sites of initial infection in the brain: the path to progressive multifocal leukoencephalopathy. J Infect Dis. 2002;186(suppl 2):S180-S186.
3. Pietropaolo V, Videtta M, Fioriti D, et al. Re-arrangement patterns of JC virus noncoding control region from different biological samples. J Neurovirol. 2003;9:603-611.
4. Van Assche G, Van Ranst M, Sciot R, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med. 2005;353:362-368.
5. Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med. 2005;353:369-374.
6. Langer-Gould A, Atlas SW, Green AJ, et al. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med. 2005;353:375-381.
7. Steinman L. Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab. Nature Rev Drug Discov. 2005;4:510-518.
8. Rice GP, Hartung HP, Calabresi PA. Anti-alpha 4 Integrin therapy for multiple sclerosis: mechanisms and rationale. Neurology. 2005;64:1336-1342.
9. Elphick GF, Querbes W, Jordan J, et al. The human polyomavirus JCV uses serotonin receptors to infect cells. Science. 2004;306:1380-1383.
10. Frisque RJ, Bollag B, Tyagarajan SK, Kilpatrick LH. T proteins influence JC virus biology. J Neurovirol. 2003;9(suppl 1):15-20.
11. Khalili K, White MK, Sawa H, et al. The agno-protein of polyomaviruses: a multifunctional auxiliary protein. J Cell Physiol. 2005; 204:1-7.
12. Dorries K, Sbiera S, Dfrews K, et al. Association of human polyomavirus JC with peripheral blood of immunoimpaired and healthy individuals. J Neurovirol. 2003;9(suppl 1):81-87.
13. Berger JR, Koralnik IJ. Progressive multifocal leukoencephalopathy with natalizumab-unforeseen consequences. N Engl J Med. 2005; 353:414-416.
14. DuPasquier RA, Schmitz JE, Jean-Jacques J, et al. Detection of JC virus-specific cytotoxic T-lymphocytes in healthy individuals. J Virol. 2004; 78:10206-10210.
15. DuPasquier RA, Kuroda MJ, Zheng Y, et al. A prospective study demonstrates an association between JC virus-specific cytotoxic T lymphocytes and the early control of progressive multifocal leukoencephalopathy. Brain. 2004;127: 1970-1978.
16. Hall CD, Dafni U, Simpson D, et al. Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. N Engl J Med. 1998; 338:1345-1351.
17. Marra CM, Rajicic N, Barker DE, et al. A pilot study of cidofovir for progressive multifocal leukoencephalopathy in AIDS. AIDS. 2002;16: 1791-1797.
18. Huang SS, Skolasky RL, Dal Pan GJ, et al. Survival prolongation in HIV-associated progressive multifocal leukoencephalopathy treated with alpha-interferon: an observational study. J Neurovirol. 1998;4:324-332.
19. Lucchinetti C, Bruck W, Parisi J, et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol. 2000;47:707-717.
20. Gran B, Zhang GX, Rostami A. Role of the IL-12/IL-23 system in the regulation of T-cell responses in central nervous system inflammatory demyelination. Crit Rev Immunol. 2004; 24:111-128.
21. Engelhardt B, Ransohoff RM. The ins and outs of T-Lymphocyte trafficking to the CNS: anatomical sites and molecular mechanisms. Trends Immunol. 2005; July 20:epub ahead of print.
22. Ferrante P, Omodeo-Zorini E, Caldarelli-Stefano R, et al. Detection of JC virus DNA in cerebrospinal fluid from multiple sclerosis patients. Mult Scler. 1998;4:49-54.
23. Hirsch HH, Brennan DC, Drachenberg CB, et al. Polyoma-virus associated nephropathy in renal transplantation: interdisciplinary analyses and recommendations. Transplantation. 2005;72:1277-1286.